# Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

> **NCT01404650** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 25 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumor

## Interventions

- **DRUG:** AUY922

## Key facts

- **NCT ID:** NCT01404650
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01404650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01404650, "Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01404650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*